Cargando…

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B

A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozlan, Yael, Aaron, Daniella, Davidov, Yana, Likhter, Maria, Ben Yakov, Gil, Cohen-Ezra, Oranit, Picard, Orit, Erster, Oran, Mendelson, Ella, Ben-Ari, Ziv, Abu Baker, Fadi, Mor, Orna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949614/
https://www.ncbi.nlm.nih.gov/pubmed/35336990
http://dx.doi.org/10.3390/v14030584
_version_ 1784674939782037504
author Gozlan, Yael
Aaron, Daniella
Davidov, Yana
Likhter, Maria
Ben Yakov, Gil
Cohen-Ezra, Oranit
Picard, Orit
Erster, Oran
Mendelson, Ella
Ben-Ari, Ziv
Abu Baker, Fadi
Mor, Orna
author_facet Gozlan, Yael
Aaron, Daniella
Davidov, Yana
Likhter, Maria
Ben Yakov, Gil
Cohen-Ezra, Oranit
Picard, Orit
Erster, Oran
Mendelson, Ella
Ben-Ari, Ziv
Abu Baker, Fadi
Mor, Orna
author_sort Gozlan, Yael
collection PubMed
description A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in peripheral lymphocytes (PBMCs) and HBV mutation profiles in CHB patients. Patient demographics (n = 139) and classical HBV biomarkers were determined during a clinical routine. HBV-RNA in plasma and HBV-DNA in PBMCs were determined by RT-PCR. HBsAg levels were determined using Architect. In samples with HBV-DNA viral load >1000 IU/mL, genotype mutations in precore (PC), basal core promoter (BCP), HBsAg and Pol regions were determined by sequencing. Most patients (n = 126) were HBeAg-negative (HBeAgNeg) with significantly lower levels of HBV-RNA, HBV-DNA and HBsAg compared to HBeAg-positive (HBeAgPos) patients (p < 0.05). HBV genotype D prevailed (61/68), and >95% had BCP/PC mutations. Escape mutations were identified in 22.6% (13/63). HBeAgNeg patients with low levels of HBsAg (log IU ≤ 3) were older and were characterized by undetectable plasma HBV-DNA and undetectable HBV-RNA but not undetectable HBV-DNA in PBMCs compared to those with high HBsAg levels. In >50% of the studied HBeAgNeg patients (66/126), the quantitation of HBsAg and HBV-RNA may impact clinical decisions. In conclusion, the combined assessment of classical and novel serum biomarkers, especially in HBeAgNeg patients, which is the largest group of CHB patients in many regions, may assist in clinical decisions. Prospective studies are required to determine the real-time additive clinical advantage of these biomarkers.
format Online
Article
Text
id pubmed-8949614
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89496142022-03-26 HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B Gozlan, Yael Aaron, Daniella Davidov, Yana Likhter, Maria Ben Yakov, Gil Cohen-Ezra, Oranit Picard, Orit Erster, Oran Mendelson, Ella Ben-Ari, Ziv Abu Baker, Fadi Mor, Orna Viruses Article A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in peripheral lymphocytes (PBMCs) and HBV mutation profiles in CHB patients. Patient demographics (n = 139) and classical HBV biomarkers were determined during a clinical routine. HBV-RNA in plasma and HBV-DNA in PBMCs were determined by RT-PCR. HBsAg levels were determined using Architect. In samples with HBV-DNA viral load >1000 IU/mL, genotype mutations in precore (PC), basal core promoter (BCP), HBsAg and Pol regions were determined by sequencing. Most patients (n = 126) were HBeAg-negative (HBeAgNeg) with significantly lower levels of HBV-RNA, HBV-DNA and HBsAg compared to HBeAg-positive (HBeAgPos) patients (p < 0.05). HBV genotype D prevailed (61/68), and >95% had BCP/PC mutations. Escape mutations were identified in 22.6% (13/63). HBeAgNeg patients with low levels of HBsAg (log IU ≤ 3) were older and were characterized by undetectable plasma HBV-DNA and undetectable HBV-RNA but not undetectable HBV-DNA in PBMCs compared to those with high HBsAg levels. In >50% of the studied HBeAgNeg patients (66/126), the quantitation of HBsAg and HBV-RNA may impact clinical decisions. In conclusion, the combined assessment of classical and novel serum biomarkers, especially in HBeAgNeg patients, which is the largest group of CHB patients in many regions, may assist in clinical decisions. Prospective studies are required to determine the real-time additive clinical advantage of these biomarkers. MDPI 2022-03-11 /pmc/articles/PMC8949614/ /pubmed/35336990 http://dx.doi.org/10.3390/v14030584 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gozlan, Yael
Aaron, Daniella
Davidov, Yana
Likhter, Maria
Ben Yakov, Gil
Cohen-Ezra, Oranit
Picard, Orit
Erster, Oran
Mendelson, Ella
Ben-Ari, Ziv
Abu Baker, Fadi
Mor, Orna
HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
title HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
title_full HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
title_fullStr HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
title_full_unstemmed HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
title_short HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
title_sort hbv-rna, quantitative hbsag, levels of hbv in peripheral lymphocytes and hbv mutation profiles in chronic hepatitis b
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949614/
https://www.ncbi.nlm.nih.gov/pubmed/35336990
http://dx.doi.org/10.3390/v14030584
work_keys_str_mv AT gozlanyael hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT aarondaniella hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT davidovyana hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT likhtermaria hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT benyakovgil hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT cohenezraoranit hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT picardorit hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT ersteroran hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT mendelsonella hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT benariziv hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT abubakerfadi hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb
AT mororna hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb